These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

278 related items for PubMed ID: 11792137

  • 1. An integrated clinical approach to predicting the benefit of tirofiban in non-ST elevation acute coronary syndromes. Application of the TIMI Risk Score for UA/NSTEMI in PRISM-PLUS.
    Morrow DA, Antman EM, Snapinn SM, McCabe CH, Theroux P, Braunwald E.
    Eur Heart J; 2002 Feb; 23(3):223-9. PubMed ID: 11792137
    [Abstract] [Full Text] [Related]

  • 2. Improved in-hospital outcomes in acute coronary syndromes (unstable angina/non-ST segment elevation myocardial infarction) despite similar TIMI risk scores.
    Almeda FQ, Hendel RC, Nathan S, Meyer PM, Calvin JE, Klein LW.
    J Invasive Cardiol; 2003 Sep; 15(9):502-6. PubMed ID: 12947210
    [Abstract] [Full Text] [Related]

  • 3. Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS)-TIMI 18 trial.
    Sabatine MS, Morrow DA, Giugliano RP, Murphy SA, Demopoulos LA, DiBattiste PM, Weintraub WS, McCabe CH, Antman EM, Cannon CP, Braunwald E.
    Circulation; 2004 Feb 24; 109(7):874-80. PubMed ID: 14757697
    [Abstract] [Full Text] [Related]

  • 4. Effect of platelet glycoprotein IIb/IIIa receptor blockade with tirofiban on adverse cardiac events in women with unstable angina/non-ST-elevation myocardial infarction (PRISM-PLUS Study).
    Huynh T, Theroux P, Snapinn S, Wan Y, Montreal General Hospital, Montreal, Quebec, Canada. thao.huynh@muhc.mcgill.ca.
    Am Heart J; 2003 Oct 24; 146(4):668-73. PubMed ID: 14564321
    [Abstract] [Full Text] [Related]

  • 5. Effects of glycoprotein IIb/IIIa inhibition on clinical stabilization parameters in patients with unstable angina and non-Q-wave myocardial infarction.
    Okmen E, Cakmak M, Tartan Z, Cam N.
    Heart Vessels; 2003 Jul 24; 18(3):117-22. PubMed ID: 12955426
    [Abstract] [Full Text] [Related]

  • 6. Tirofiban therapy for patients with acute coronary syndromes and prior coronary artery bypass grafting in the PRISM-PLUS trial.
    Servoss SJ, Wan Y, Snapinn SM, DiBattiste PM, Zhao XQ, Theroux P, Jang IK, Januzzi JL, PRISM-PLUS trial.
    Am J Cardiol; 2004 Apr 01; 93(7):843-7. PubMed ID: 15050486
    [Abstract] [Full Text] [Related]

  • 7. Usefulness of tirofiban among patients treated without percutaneous coronary intervention (TIMI high risk patients in PRISM-PLUS).
    Morrow DA, Sabatine MS, Antman EM, Cannon CP, Braunwald E, Theroux P.
    Am J Cardiol; 2004 Sep 15; 94(6):774-6. PubMed ID: 15374786
    [Abstract] [Full Text] [Related]

  • 8. Early cardiac catheterization is associated with lower mortality only among high-risk patients with ST- and non-ST-elevation acute coronary syndromes: observations from the OPUS-TIMI 16 trial.
    Cantor WJ, Goodman SG, Cannon CP, Murphy SA, Charlesworth A, Braunwauld E, Langer A.
    Am Heart J; 2005 Feb 15; 149(2):275-83. PubMed ID: 15846265
    [Abstract] [Full Text] [Related]

  • 9. Initial experience with the low-molecular-weight heparin, enoxaparin, in combination with the platelet glycoprotein IIb/IIIa blocker, tirofiban, in patients with non-ST segment elevation acute coronary syndromes.
    Cohen M.
    J Invasive Cardiol; 2000 Dec 15; 12 Suppl E():E5-9;discussion E25-8. PubMed ID: 11156722
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Validated risk score predicts the development of congestive heart failure after presentation with unstable angina or non-ST-elevation myocardial infarction: results from OPUS-TIMI 16 and TACTICS-TIMI 18.
    Wylie JV, Murphy SA, Morrow DA, de Lemos JA, Antman EM, Cannon CP.
    Am Heart J; 2004 Jul 15; 148(1):173-80. PubMed ID: 15215808
    [Abstract] [Full Text] [Related]

  • 16. Predicting a late positive serum troponin in initially troponin-negative patients with non-ST-elevation acute coronary syndrome: clinical predictors and validated risk score results from the TIMI IIIB and GUSTO IIA studies.
    Januzzi JL, Newby LK, Murphy SA, Pieper K, Antman EM, Morrow DA, Sabatine MS, Ohman EM, Cannon CP, Braunwald E.
    Am Heart J; 2006 Feb 15; 151(2):360-6. PubMed ID: 16442899
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Platelet glycoprotein inhibitors in patients with medically managed acute coronary syndrome: does the enthusiasm exceed the science?
    Schriger DL, Herbert ME.
    Ann Emerg Med; 2001 Sep 15; 38(3):249-55. PubMed ID: 11524643
    [Abstract] [Full Text] [Related]

  • 19. Plasma markers of endothelial damage/dysfunction, inflammation and thrombogenesis in relation to TIMI risk stratification in acute coronary syndromes.
    Lee KW, Blann AD, Lip GY.
    Thromb Haemost; 2005 Nov 15; 94(5):1077-83. PubMed ID: 16363252
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.